FDA to rescind breakthrough for BMS's daclatasvir

Bristol-Myers Squibb Co. (NYSE:BMY) said FDA told the company that it plans to rescind breakthrough therapy designations for

Read the full 187 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE